Objective The purpose of this study is to observe the difference of the six-month mortality,complications and function recovery between the skeletal traction group and DHS group.Methods This retrospective study was undergone in the department of orthopaedics of Longhua hospital.According to the methods of tareatment,87 cases were divided into two groups:skeletal traction group and DHS group.To comapare the rate of six-month moaality,general complications(which include pulmonary infeetion,bed-sore,minary infection and deep venous thrombosis)and coxa yams between the two groups,while the Harris hip score in the third month and sixth month after injury were also compared.Reuslt ①About the rate of six-month momdity,there was one case(2.27%) in the skeletal traction group,and one ease also(2.33%) in the DHS group,there was no difference between the two groups.(P=1.0) ②About the rate of general complications,there were 15 cases(34.09%) in the skeletal traction group,and 14 cases(32.56%) in the DHS group,there was no difference between the two groups.(P=0.879) ③About the rate of coxa varus,there were seven eases (16.28%) in the skeletal traction group,and one ease(2.38%)in the DHS group,there was no difference between the two groups.(P=0.068).But for the unstable intertrochantefic fractures,there were seven cases out of 29(24.14%)in the skeletal traction group,and one case out of 31 (3.23%),these showed that the rate of coxa yams is higher in the skeletal traction group than in the DHS group.(P=0.045) ④In the third month after injury,the Harris hip score was 52.99±4.86 in the skeletal traction group,and 65.87±3.39 in the DHS group,these showed that the Harris hip score is higher in the DHS group than in the skeletal traction group(P<0.0001).While in the sixth month after injury,the Harris hip score was 84.44±5.79 in the skeletal traction group,and 85.69±4.07 in the DHS group,these showed that there was no difference between the two groups(P=0.254).Conclusion ① A low mortality and complications morbidity co
目的：观察自体细胞生长因子关节腔注射联合佩戴人工膝关节支具治疗膝骨关节炎的临床疗效及安全性。方法：2014年6月至2015年3月,采用自体细胞生长因子关节腔注射联合佩戴人工膝关节支具治疗膝骨关节炎患者36例,男8例、女28例。年龄49-67岁,中位数55岁。病程4-24个月,中位数15.5个月。分别于治疗前及治疗开始后1 d、1个月、3个月、6个月测定患者的西安大略和麦克马斯特大学（Western Ontario and Mc Master Universities,WOMAC）骨关节炎指数评分,比较治疗前及治疗开始后6个月的膝关节内侧胫股关节间隙宽度,观察不良反应和并发症发生情况。结果：所有患者均获随访,随访时间6-12个月,中位数8个月。治疗及随访过程中均未出现任何不良反应和并发症。WOMAC骨关节炎指数评分,治疗前（46.5±7.3）分,治疗开始后1 d（40.4±6.5）分、1个月（32.2±4.7）分、3个月（30.5±5.1）分、6个月（27.8±4.6）分。治疗开始后6个月膝关节内侧胫股关节间隙宽度大于治疗前[（2.2±0.6）mm,（3.3±0.5）mm,t=8.450,P=0.000]。结论：自体细胞生长因子关节腔注射联合佩戴人工膝关节支具治疗膝骨关节炎,能够有效改善膝关节功能、增大内侧胫股关节间隙,且安全性好,值得临床推广应用。
目的:观察膝关节骨性关节炎患者在体外人工膝外翻支具辅助下行自体细胞生长因子关节腔注射疗法的治疗效果。方法:选取50例单膝内侧间室骨性关节炎患者,给予细胞生长因子关节腔序贯注射治疗,并同时佩戴体外人工膝外翻支具。本组患者男12例,女38例;年龄45~71岁,平均(55.2±7.8)岁;病程3~24个月,平均(14.8±5.8)个月。细胞生长因子每周注射2次,每次5 m L,连续5次为1疗程,每个患者注射1个疗程。体外人工膝外翻支具每天佩戴时间1~4 h,根据患者耐受程度进行调整,至少连续佩戴6个月。治疗前及治疗后1天、1个月、3个月及6个月进行WOMAC骨关节炎指数评分,并在治疗前及治疗后6个月时拍摄患膝站立位X线片,比较内侧胫股关节间隙宽度。结果:所有患者均得到6~12个月的随访,平均随访时间(8.2±1.9)个月,治疗前、治疗后1天、1个月、3个月及6个月的WOMAC评分分别为(46.5±7.3),(40.4±6.5),(32.2±4.7),(30.5±5.1)和(27.8±4.6)分。治疗后1天,WOMAC评分较治疗前显著减少,差异有统计学意义(t=3.74,P<0.001);治疗后1个月时WOMAC评分继续明显下降,差异有统计学意义(t=6.13,P<0.01);治疗后3个月评分无明显变化,差异无统计学意义(t=1.47,P=0.15);6个月后WOMAC评分再次明显下降,差异有统计学意义(t=2.36,P=0.02)。内侧胫股关节间隙治疗前(2.1±0.7)mm,治疗后6个月随访时(3.2±0.6)mm,差异有统计学意义(t=8.45 P<0.01)。结论:细胞生长因子关节腔序贯注射联合体外人工膝外翻支具治疗膝内侧单间室骨性关节炎疗效明显。
